The Danish Non-vitamin K Antagonist Oral Anticoagulation Study. A Cluster Randomized Study Comparing Safety and Efficacy of Edoxaban, Apixaban, Rivaroxaban and Dabigatran for Oral Anticoagulation in Atrial Fibrillation (DANNOAC-AF).
Phase of Trial: Phase IV
Latest Information Update: 05 May 2017
Price : $35 *
At a glance
- Drugs Apixaban (Primary) ; Dabigatran etexilate (Primary) ; Edoxaban (Primary) ; Rivaroxaban (Primary)
- Indications Myocardial infarction; Stroke; Thromboembolism
- Focus Therapeutic Use
- Acronyms DANNOAC-AF
- 30 Apr 2017 Status changed from not yet recruiting to recruiting.
- 28 Apr 2017 New trial record